Lantern Pharma Inc. Achieves Milestone in ADC Program with Novel Cryptophycin Drug-Payload

Lantern Pharma Inc. proudly announces a significant advancement in its antibody-drug conjugate (ADC) program, achieved through a collaborative effort with Bielefeld University. This milestone marks the successful development of a novel class of ADCs, leveraging the potent and specific cryptophycin as the drug payload. Employing a strategic approach focused on biologically relevant targets and efficient drug conjugate formats, Lantern demonstrates its commitment to pioneering cancer therapeutics.

By utilizing cysteine-engineered antibodies, Lantern ensures uniformity and precision in ADCs, offering precise control over the drug-to-antibody ratio (DAR). The utilization of cryptophycin as the drug payload holds immense promise, potentially enhancing the anti-tumor potency of ADC molecules while overcoming common drug resistance issues. Preliminary preclinical studies have shown remarkable efficacy, with cryptophycin-ADC (CpADC) outperforming existing payloads like MMAE (Monomethyl auristatin E) across various cancer cell lines. This achievement underscores Lantern's dedication to advancing cancer therapy innovation and improving patient outcomes.